Trial Profile

A Phase 1b, Multicenter, Open Label Study to Evaluate the Safety, Pharmacokinetics and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 01 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tegoprubart (Primary) ; Antithymocyte globulin; Mycophenolate mofetil; Steroids
Indications Renal transplant rejection
Focus Adverse reactions; Pharmacokinetics
Sponsors Eledon Pharmaceuticals

22 Jun 2026 According to an Eledon Pharmaceuticals media release, in the phase 1b study, long-term data were available for 16 patients, with eight patients followed through 24 months and the longest-followed ongoing patient remaining on tegoprubart for approximately 3.5 years.
23 Jan 2026 Results presented in the Eledon Pharmaceuticals media release.
08 Jan 2026 According to an Eledon Pharmaceuticals media release, long-term data from the Phase 1 and Phase 2 BESTOW studies evaluating tegoprubart in kidney transplantation is anticipated to be reported in 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com